Showing results (121-130 of 230) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase InhibitorAngelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, et al.
Gynecologic Oncology|May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancerElizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Gynecologic Oncology Reports|March 1, 2024
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancerPanagiotis A Konstantinopoulos, Niya Xiong, Carolyn Krasner, et al.
Journal of Alternative and Complementary Medicine (New York, N.Y.)|June 26, 2009
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trialWeidong Lu, Ursula A Matulonis, Anne Doherty-Gilman, et al.
Oncotarget|February 13, 2016
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancerKyle C Strickland, Brooke E Howitt, Sachet A Shukla, et al.
JAMA Oncology|July 17, 2015
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1Brooke E Howitt, Sachet A Shukla, Lynette M Sholl, et al.
Molecular Cancer Therapeutics|January 26, 2019
Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of ResponsivenessClaudia Iavarone, Ioannis K Zervantonakis, Laura M Selfors, et al.
Future Oncology (London, England)|September 6, 2022
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)Panagiotis A Konstantinopoulos, Antonio Gonzalez-Martin, Felipe Melo Cruz, et al.
Gynecologic Oncology|March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancerDebra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Gynecologic Oncology|September 14, 2023
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigueAlexi A Wright, Hanneke Poort, Anna Tavormina, et al.
Pageof 23